Status: Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK5460025 alone or in combination (potential combinations may be included in future amendments to the protocol) with other anti-cancer agents can decrease tumor size, is safe, well-tolerated, and how the drug is processed in the body over time.
Participants needed: 47
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: GlaxoSmithKlineUpdated: Sep 16, 2026Locations: 27
Eligibility criteria
Has a histologically diagnosed advanced (unresectable, metastatic or recurrent)... [+9]
Has not recovered (i.e., to Grade ≤1 or to baseline) from prior anticancer thera... [+7]